Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00733720 · ClinicalTrials.gov registry record · Phase 1
Buprenorphine Naltrexone-P1 A-Cocaine
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00733720 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 8 participants.
The verdict
NCT00733720, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of oral naltrexone. This study will provide data to support the design of a similar study of the depot formulation of naltrexone and ultimately to study this combination for the treatment of cocaine dependence.
Interventions
- DRUG Suboxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00733720
The ClinicalTrials.gov registry entry for NCT00733720 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Suboxone is the first listed.
NCT00733720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00733720 about?
NCT00733720 is a clinical study titled "Buprenorphine Naltrexone-P1 A-Cocaine". The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of oral naltrexone. This study will provide data to support the design of a similar study of the depot formulation of naltrexon...
What is the current status of trial NCT00733720?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-08. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00733720?
The interventions under investigation include: Suboxone (DRUG).
Who is sponsoring clinical trial NCT00733720?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.